NRG Oncology is soliciting PILOT projects for applications focused on NRG NCORP Cancer Prevention and Control (CPC) priorities that will provide data that will directly lead to future Phase II-III CPC concepts. As put forward in our core grant, CPC priorities for funding are:

- Cancer prevention research aimed at identifying and evaluating interventions to reduce the risk and incidence of cancer; priority will be given to concepts in women’s health, and other concepts are welcome
- Cancer control research aimed at reducing the incidence and co-morbidity of cancer and its treatment focused on the four symptomatic management themes: neurotoxicity, cardiotoxicity, lymphedema, and inflammation (including cancer-related fatigue)
- Survivorship and palliative care interventions aimed at reducing toxicity and symptom burden, and improving quality of life (QoL)
- Cancer disparity research, in collaboration with our Health Disparities Research (HDR) Program, focused on efforts to increase the participation of minorities and underserved populations in CPC studies

Integral to these priorities, are the establishment of biospecimen repositories for molecular studies.

Funding can be requested for up to $18,000 and is contingent upon NRG Oncology’s receipt of the Notice of Award from the Division of Cancer Prevention. One to two projects may be funded. Projects are to be implemented September 1, 2017 and completed by December 31, 2018. **No carry over funds will be issued and an interim progress report is due within 6 months and a completed progress report is due at the end of the project period. Institutions who allow total award to fund research (and waive in-directs) will be given priority.**

**Background**

The NRG NCORP core grant focuses on continued leadership in cancer prevention and control (CPC) research. Our CPC objectives will benefit the NCTN Program through continued research across the breadth of NRG disease sites with a unique focus in both women’s health, attributable to our gynecologic and breast cancer expertise, and technology assessment, through the world’s largest radiotherapy (RT) focused research base. CPC will design and conduct trials to assess cancer prevention, reduce the burden of cancer treatment-related symptoms across solid tumor disease sites with an emphasis on the prevention of women’s cancers, and a focus on high prevalence symptoms in our population.

**Instructions for Applicants**

If you have an interest in this application, please submit a [5 page proposal to fielde@nrgoncology.org by 5pm ET, Friday, May 5, 2017.**
• Description of project, including summary of specific aims
• **How the project will help lead to a Phase II or Phase III NCORP concept**
• Are NRG Oncology resources required? (i.e. biospecimen materials, statistical support, etc)
• Investigators who will participate in project
• Timeline [not included in the 5 page limit]
• NIH biosketch of PI [not included in the 5 page limit]
• Detailed budget [not included in the 5 page limit]

**Submit applications to:**
Erica Field, MPH, MHA, CCRP
Project Administrator
fiede@nrgoncology.org
215-940-8824

**Direct scientific questions to NRG NCORP Co-Chairs:**
Deborah Watkins Bruner, RN, PhD, FAAN
Larry Wickerham, MD
deborah.w.bruner@emory.edu
wickerhamd@nrgoncology.org

Joan Walker, MD
Joan-walker@ouhsc.edu